catalyst version 4.11 (Hypogen Inc)
90
Structured Review
Hypogen Inc
catalyst version 4.11
Catalyst Version 4.11, supplied by Hypogen Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/discovery+studios+catalyst+hypogen+algorithm/software+catalyst+hypogen/pmc04632247-316-7-11
Average 90 stars, based on 1 article reviews
Catalyst Version 4.11, supplied by Hypogen Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/discovery+studios+catalyst+hypogen+algorithm/software+catalyst+hypogen/pmc04632247-316-7-11
Average 90 stars, based on 1 article reviews
catalyst version 4.11 - by Bioz Stars,
2026-10
90/100 stars
Images
Related Articles
other:Article Title: Determination and modelling of stereoselective interactions of ligands with drug transporters: A key dimension in the understanding of drug disposition Article Snippet: The Article Title: Poster presentation abstracts Article Snippet: Poster presentation abstracts Springer Science+Business Media, LLC 2010 Session I (18-02-2010) DESIGN, SYNTHESIS AND CHARACTERIZATION OF SOME NOVEL 1,3,4-THIADIAZOLE DERIVATIVES AS POSSIBLE ANTICONVULSANT AGENTS Abhishek Soni, Sushil.. K. Kashaw Pharmaceutical Chemistry Division, Department of Pharmaceutical Sciences, Dr. H. S. Gour University, Sagar, 470003, MP, India. e-mail: sonipharma@gmail.com 1,3,4-Thiadiazole exhibits various biological activities such as, anti-inflammatory, anticonvulsant, antibacterial, antitubercular, antifungal, anti-viral and antimicrobial activity.. Two novel series A (1–5) N-(5-sulfanyl-1,3,4-thiadiazol-2-yl)hydrazinecarboxamide and B (1–3) 1-(5-sulfanyl-1,3,4-thiadiazol2-yl)urea have been synthesized. Article Title: Toxin-related antibodies with antimicrobial and antiviral activity Article Snippet: Article Title: Structure-based hepatitis C virus drug design Article Snippet: Pharmacophores can be determined using software such as Article Title: Exploring Enantiospecific Ligand-Protein Interactions Using Cellular Membrane Affinity Chromatography: Chiral Recognition as a Dynamic Process Article Snippet: The Generated:Article Title: Advances in the Design and Synthesis of Prazosin Derivatives over the Last Ten Years Article Snippet: .. Those pharmacophores were generated using the HypoGen algorithm in Article Title: Ligand-based and structure-based approaches in identifying ideal pharmacophore against c-Jun N-terminal kinase-3. Article Snippet: Structure and ligand based pharmacophore modeling and docking studies carried out using diversified set of c-Jun N-terminal kinase-3 (JNK3) inhibitors are presented in this paper.. Ligand based pharmacophore model (LBPM) was developed for 106 inhibitors of JNK3 using a training set of 21 compounds to reveal structural and chemical features necessary for these molecules to inhibit JNK3.. Hypo1 consisted of two hydrogen bond acceptors (HBA), one hydrogen bond donor (HBD), and a hydrophobic (HY) feature with a correlation coefficient (r) of 0.950. Software:Article Title: Advances in the Design and Synthesis of Prazosin Derivatives over the Last Ten Years Article Snippet: .. Those pharmacophores were generated using the HypoGen algorithm in Article Title: Molecular modelling and docking studies on heat shock protein 90 (Hsp90) inhibitors. Article Snippet: Taylor & Francis makes every effort to ensure the accuracy of all the information (the “Content”) contained in the publications on our platform.. However, Taylor & Francis, our agents, and our licensors make no representations or warranties whatsoever as to the accuracy, completeness, or suitability for any purpose of the Content.. Any opinions and views expressed in this publication are the opinions and views of the authors, and are not the views of or endorsed by Taylor & Francis. Article Title: Ligand-based and structure-based approaches in identifying ideal pharmacophore against c-Jun N-terminal kinase-3. Article Snippet: Structure and ligand based pharmacophore modeling and docking studies carried out using diversified set of c-Jun N-terminal kinase-3 (JNK3) inhibitors are presented in this paper.. Ligand based pharmacophore model (LBPM) was developed for 106 inhibitors of JNK3 using a training set of 21 compounds to reveal structural and chemical features necessary for these molecules to inhibit JNK3.. Hypo1 consisted of two hydrogen bond acceptors (HBA), one hydrogen bond donor (HBD), and a hydrophobic (HY) feature with a correlation coefficient (r) of 0.950. |